Schmallenberg vaccine produced
In a very short timeframe research was able to produce a vaccine and it was demonstrated that vaccinated animals were protected against a challenge with Schmallenberg virus.
The results of several studies were presented as a poster presentation at a satellite symposium on the Schmallenberg virus during the 6th Annual Meeting of EPIZONE (an international network of veterinary research institutes working on epizootic animal diseases), which took place in Brighton (United Kingdom) from June 13-15, 2012.
The vaccine is based on wild-type Schmallenberg virus that has been inactivated and contains an adjuvant that stimulates the immune response. In the studies to date, safety and efficacy has been demonstrated in calves, lambs and pregnant ewes.
“In our studies we looked at the serological response as well as viremia and we have now reported that all vaccinated animals responded with formation of virus neutralizing antibodies. During the trials, all vaccinated animals were protected against Schmallenberg virus infection (complete blockage of viremia), whereas all controls developed viremia after challenge. Moreover, we found a good correlation between antibody titers and viremia”, said Veronique Moulin, research scientist at the virological R&D department at MSD Animal Health.
“Using our experience gained a few years ago during the fast-track development of the first vaccine against bluetongue 8 virus in just 21 months, we are now on track to develop a vaccine against Schmallenberg virus in an even shorter time. After we isolated the virus last December, we have diligently worked in an integrated and interdisciplinary team at BioSciences Center Boxmeer (the Netherlands) and our manufacturing site in Burgwedel (Germany) to develop this vaccine. We anticipate, pending regulatory approvals, to have a vaccine available for our customers by the end of this year”, said Dr. Rene Aerts, vice president Global Biologicals R&D Animal Health.
“Since the emergence of the Schmallenberg virus late summer of 2011, it has spread across several countries in Europe. At this moment it is not possible to predict the course and impact of the endemic in Europe in the near future. We see a potential role for the vaccine in the protection of young breeding stock on infected farms and protection of non-infected farms in risk areas" said Dr. Aerts.
No comments posted yet. Be the first to post a comment
Please enter your name
Please enter your comment
Your comment submitted successfully.Please wait for admin approval.
Some error on your process.Please try one more time.
Membership of the EU is damaging the British farming industry, according to...
BASIS has launched an accreditation for pilots of Unmanned Aerial Systems (...
UK wheat yields have theoretical potential to more than double over the nex...
Britain’s farmers flocked to Peterborough for the first day of LAMMA’15 to ...
The crisis in the dairy industry is not the fault of supermarkets, accordin...
Transport Minister Baroness Kramer visited three rural businesses in Cheshi...
Spearheading the John Deere range of mid-size tractors from Mannheim, the n...
Regular testing for bovine TB could significantly reduce the number of infe...
Single-issue policy-making threatens to hamper, not help, the progress of U...